Rosenberg Sa
Impact in
-
- Lymphoma Diagnosis and Treatment
- Oncology top 5%
- Viral-associated cancers and disorders
- Vascular Tumors and Angiosarcomas
Papers in
-
- Lymphoma Diagnosis and Treatment 17
- Genetic factors in colorectal cancer 4
-
- Lung Cancer Treatments and Mutations 10
- Sarcoma Diagnosis and Treatment 5
- Co-authors
- Kaplan Hs (9 shared papers)Dorfman Rf (3 shared papers)Yutaka Kawakami (1 shared paper)Elizabeth Stevens (1 shared paper)Mona El‐Gamil (1 shared paper)Nelsen Ts (2 shared papers)Eli Glatstein (1 shared paper)NR Dunnick (1 shared paper)
- Journals
- Oncology nursing forum (1 paper)PubMed (39 papers)
- Partner nations
- United StatesFrance
In The Last Decade
Rosenberg Sa
37 papers receiving 1.3k citations
Peers
Comparison fields: 5 of 85
- Pathology and Forensic Medicine 561
- Oncology 585
- Immunology 355
- Genetics 162
- Pulmonary and Respiratory Medicine 400
Countries citing papers authored by Rosenberg Sa
This map shows the geographic impact of Rosenberg Sa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rosenberg Sa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rosenberg Sa more than expected).
Fields of papers citing papers by Rosenberg Sa
This network shows the impact of papers produced by Rosenberg Sa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rosenberg Sa. The network helps show where Rosenberg Sa may publish in the future.
Co-authors
The 25 scholars most cited alongside Rosenberg Sa, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 40 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. | 1994 | 207 |
| 2 | Validity of the Ann Arbor staging classification for the non-Hodgkin's lymphomas. | 1977 | 177 |
| 3 | Early lymphatic spread of osteogenic and soft-tissue sarcomas. | 1978 | 134 |
| 4 | Clinical and surgical (laparotomy) evaluation of patients with non-Hodgkin's lymphomas. | 1977 | 130 |
| 5 | Prospective randomized evaluation of the role of limb-sparing surgery, radiation therapy, and adjuvant chemoimmunotherapy in the treatment of adult soft-tissue sarcomas. | 1978 | 109 |
| 6 | Adoptive immunotherapy of cancer: accomplishments and prospects. | 1984 | 85 |
| 7 | Staging laparotomy and splenectomy in Hodgkin's disease: analysis of indications and patterns of involvement in 285 consecutive, unselected patients. | 1973 | 62 |
| 8 | Prognostic factors in pathologic stage III Hodgkin's disease. | 1982 | 47 |
| 9 | Prospective randomized trials demonstrating the efficacy of adjuvant chemotherapy in adult patients with soft tissue sarcomas. | 1984 | 42 |
| 10 | Immunotherapy of patients with advanced cancer using interleukin-2 alone or in combination with lymphokine activated killer cells. | 1988 | 42 |
| 11 | Combined modality therapy in malignant lymphomas. | 1977 | 39 |
| 12 | Third-line chemotherapy for resistant Hodgkin's disease with lomustine, etoposide, and methotrexate. | 1987 | 36 |
| 13 | Pathology of malignant lymphomas in the liver: application in staging. | 1976 | 31 |
| 14 | Chemotherapy of the non-Hodgkin's lymphomas: the Stanford experience. | 1977 | 29 |
| 15 | Adoptive immunotherapy of renal cell carcinoma: studies from the Surgery Branch, National Cancer Institute. | 1993 | 26 |
| 16 | Immunotherapy of cancer with lymphokine-activated killer cells and recombinant interleukin-2. | 1985 | 22 |
| 17 | The concept, evolution and preliminary results of the current Stanford clinical trials for Hodgkin's disease. | 1985 | 21 |
| 18 | Intellectually handicapped mothers: problems and prospects. | 1982 | 20 |
| 19 | Clinical trials in the non-Hodgkin's lymphomata at Stanford University experimental design and preliminary results. | 1975 | 19 |
| 20 | Inhibition of pokeweed mitogen-induced immunoglobulin production in humans by gold compounds. | 1979 | 19 |
About Rosenberg Sa
Rosenberg Sa is a scholar working on Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine, Oncology, Immunology and Genetics, having authored 40 papers that have together received 1.4k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (17 papers), Immunotherapy and Immune Responses (10 papers), Lung Cancer Treatments and Mutations (10 papers), Sarcoma Diagnosis and Treatment (5 papers), Vascular Tumors and Angiosarcomas (5 papers), Chronic Lymphocytic Leukemia Research (4 papers), Genetic factors in colorectal cancer (4 papers) and Cancer Immunotherapy and Biomarkers (3 papers). The work is most often cited by research in Pathology and Forensic Medicine (561 citations), Oncology (585 citations), Immunology (355 citations), Genetics (162 citations) and Pulmonary and Respiratory Medicine (400 citations). Rosenberg Sa has collaborated with scholars based in United States and France. Frequent co-authors include Kaplan Hs, Dorfman Rf, Yutaka Kawakami, Elizabeth Stevens, Mona El‐Gamil, Nelsen Ts, Eli Glatstein, NR Dunnick, Ronald A. Castellino and R Warnke. Their work appears in journals such as Oncology nursing forum and PubMed.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.